嵌合抗原受体
重置(财务)
肌炎
CD19
医学
肌病
抗原
免疫系统
免疫学
受体
T细胞
内科学
金融经济学
经济
作者
J. Volkov,Daniel Núñez,Tahseen Mozaffar,Jason Stadanlick,Mallorie Werner,Z. Vorndran,Alexandra G. Ellis,Jazmean K. Williams,Justin Cicarelli,Quynh Lam,Thomas Furmanak,Chris Schmitt,Fatemeh Hadi-Nezhad,Daniel Thompson,Claire Miller,Courtney Little,David Chang,Samik Basu
标识
DOI:10.1016/j.ymthe.2024.09.009
摘要
Under compassionate use, chimeric antigen receptor (CAR) T cells have elicited durable remissions in patients with refractory idiopathic inflammatory myopathies (IIMs). Here, we report on the safety, efficacy, and correlative data of the first subject with the immune-mediated necrotizing myopathy (IMNM) subtype of IIM who received a fully human, 4-1BBz anti-CD19-CAR T cell therapy (CABA-201) in the RESET-Myositis phase I/II trial (NCT06154252). CABA-201 was well-tolerated following infusion. Notably, no evidence of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was observed. Creatine kinase levels decreased, and muscular strength improved post-infusion. Peripheral B cells were depleted rapidly following infusion, and the subject achieved peripheral B cell aplasia by day 15 post-infusion. Peripheral B cells returned at 2 months post-infusion and were almost entirely transitional. Autoantibodies to SRP-9, SRP-72, SRP-54, and Ro-52, decreased relative to baseline, whereas antibodies associated with pathogens and vaccinations remained stable. The infusion product consisted of predominantly CD4+ effector memory T cells and exhibited in vitro cytolytic activity. Post-infusion, CABA-201 expansion peaked at day 15 and was preceded by a serum IFN-γ peak on day 8 with peaks in serum IL-12p40 and IP-10 on day 15. These data detail the safety, efficacy, and pharmacodynamics of CABA-201 in the first IMNM subject.
科研通智能强力驱动
Strongly Powered by AbleSci AI